ArticleInternational journal of legal medicine2026
Fatal atomoxetine overdose in Japan: a forensic autopsy case report.
Article in International journal of legal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atomoxetine has been widely used worldwide for treating attention-deficit/hyperactivity disorder. In Japan, it has been prescribed since 2009 for children and since 2012 for adults. However, no forensic autopsy cases have been reported wherein atomoxetine was identified as the primary cause of death from acute intoxication. This report describes a case of fatal acute atomoxetine intoxication in a woman in her late 20s. Prior to her death, the patient had taken several prescribed medications including atomoxetine. Cardiac blood screening, performed using a semi-quantitative analysis, detected 7-aminoflunitrazepam, 7-aminonitrazepam, allylisopropylacetylurea, aripiprazole, atomoxetine, bromazepam, and suvorexant. Among these substances, the blood concentrations of atomoxetine and bromazepam exceeded their respective therapeutic ranges previously reported in the literature. A validated quantitative analysis of two compounds was performed using ultra-high-performance liquid chromatography-tandem mass spectrometry. The atomoxetine and bromazepam concentrations were 23.2 and 0.71 µg/mL in femoral blood and 24.0 and 0.78 µg/mL in cardiac blood. In conclusion, the cause of death was primarily due to acute atomoxetine intoxication, with bromazepam excluded as a direct contributing factor.
Indexed as
Identifiers
41276678What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.